



N-2106121201010001

M. D. (Pharmacology) Examination

June/July - 2021

General Pharmacology &  
Applied Sciences : Paper - I

Time : 3 Hours]

[Total Marks : 100

Instruction :

નીચે દર્શાવેલ નિશાનીવાળી વિગતો ઉત્તરવહી પર અવશ્ય લખવી. Fillup strictly the details of signs on your answer book.	Seat No. :
Name of the Examination :	<input type="text"/>
<input type="checkbox"/> M. D. (Pharmacology)	<input type="text"/>
Name of the Subject :	<input type="text"/>
<input type="checkbox"/> General Pharmacology & Applied Sciences - I	<input type="text"/>
Subject Code No. :	<input type="text"/>
<input type="checkbox"/> Section No. (1, 2,.....): Nil	<input type="text"/>
<input type="text" value="2 1 0 6 1 2 1 2 0 1 0 1 0 0 0 1"/>	<input type="text"/>
	Student's Signature

- 1 Explain in detail about various mechanisms by which drugs produce their action by giving suitable examples. 40
- 2 Describe each of the following: 30
  - (a) Pharmacogenomics.
  - (b) Issues and challenges faced while prescribing for geriatric population.
- 3 Write notes on : 30
  - (a) Role of Placebo
  - (b) Saturation kinetics
  - (c) Enterohepatic circulation.



N-2106121201020001

M. D. Examination

June/July - 2021

Pharmacology : Paper - II  
(Systemic Pharmacology, Chemotherapy & Therapeutics)

Time : 3 Hours]

[Total Marks : 100

Instruction :

नीचे दशविवेक निशानीवाणी विगतो उत्तरवडी पर अवश्य लपनी.  
Fillup strictly the details of signs on your answer book.

Name of the Examination :  
M. D.

Name of the Subject :  
Pharmacology - II (Systemic Pharmaco., Chemothe. & Therapeu.)

Subject Code No. : 2 1 0 6 1 2 1 2 0 1 0 2 0 0 0 1

Section No. (1, 2,.....): Nil

Seat No. :

--	--	--	--	--	--

Student's Signature

- 1 Discuss in details about the pharmacology, clinical status and limitations of both old and new drugs used in the treatment of Malaria. 40
- 2 Describe each of the following : 30  
(A) Nosocomial infections  
(B) Treatment of MDR tuberculosis.
- 3 Write notes on : 30  
(A) Protease inhibitors  
(B) Non-endocrine uses of corticosteroids  
(C) Drugs used in Gout.



N-2106121201030001

M. D. Examination

June/July - 2021

Pharmacology : Paper - III  
(Experimental Pharmacology, Bioassay,  
Biostatistics & Systemic Pharmacology)

Time : 3 Hours]

[Total Marks : 100

Instruction :

नीचे दशदिवे निशानीवाणी विगतो उत्तरवडी पर अवश्य लपवी.  
Fillup strictly the details of signs on your answer book.

Name of the Examination :  
M. D.

Name of the Subject :  
Pharmacology - III (Experimental Pharmacology, Bioassay, Biostat. & Systemic Pharmacology)

Subject Code No. : Section No. (1, 2,.....): Nil

2 1 0 6 1 2 1 2 0 1 0 3 0 0 0 1

Seat No. :  
[ ] [ ] [ ] [ ] [ ] [ ]

Student's Signature

- 1 Describe various animals models/techniques/instruments used for evaluation of anti-inflammatory drugs. 40
- 2 Describe each of the following : 30  
(A) CPCSEA guidelines  
(B) Bioassay in experimental animals
- 3 Write notes on : 30  
(A) Non-parametric tests of significance  
(B) Sample size determination  
(C) Drugs used in the treatment of inflammatory bowel disease



N-2106121201040001

M. D. Examination

June/July - 2021

Clinical Pharmacology & Recent Advances

Time : 3 Hours]

[Total Marks : 100

Instruction :

नीचे दशांश विधि निशानिवाणी विगतो उत्तरवही पर अवश्य कपवी. Fillup strictly the details of signs on your answer book.	Seat No. :
Name of the Examination :	<input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
M. D.	<div style="border: 1px solid black; border-radius: 15px; padding: 10px; text-align: center;">Student's Signature</div>
Name of the Subject :	
Clinical Pharmacology & Recent Advances	
Subject Code No. : Section No. (1, 2,.....) : Nil	
2 1 0 6 1 2 1 2 0 1 0 4 0 0 0 1	

- 1 Write in detail about essential documents required for conducting a clinical trial. 40
- 2 Describe each of the following: 30
  - (A) Study designs
  - (B) Discuss recent advances in drug therapy of Diabetes Mellitus
- 3 Write notes on: 30
  - (A) Confidence interval
  - (B) Microdosing
  - (C) Endothelin receptor agonists and antagonists